AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	14.56	14.07	14.76	12.75	4.67	1.27
Research & Development	24.57	40.49	54.87	29.51	16.91	6.02
Operating Expenses	39.13	54.55	69.64	42.26	21.57	7.28
Operating Income	-39.13	-54.55	-69.64	-42.26	-21.57	-7.28
Interest & Investment Income	3.99	5.47	4.86	-	0.07	0
Currency Exchange Gain (Loss)	-	-	-	-	-0.04	-
Other Non Operating Income (Expenses)	-0	-	0.04	1.31	-	-6.32
EBT Excluding Unusual Items	-35.15	-49.09	-64.73	-40.96	-21.54	-13.6
Merger & Restructuring Charges	-2.23	-2.23	-	-	-	-
Pretax Income	-37.38	-51.32	-64.73	-40.96	-21.54	-13.6
Net Income	-37.38	-51.32	-64.73	-40.96	-21.54	-13.6
Preferred Dividends & Other Adjustments	-	-	-	1.82	6.52	0.98
Net Income to Common	-37.38	-51.32	-64.73	-42.78	-28.06	-14.58
Shares Outstanding (Basic)	30	30	24	15	3	3
Shares Outstanding (Diluted)	30	30	24	15	3	3
Shares Change (YoY)	4.21%	26.39%	53.85%	481.46%	2.71%	0.61%
EPS (Basic)	-1.25	-1.72	-2.74	-2.79	-10.64	-5.68
EPS (Diluted)	-1.25	-1.72	-2.74	-2.79	-10.64	-5.68
EBIT	-39.13	-54.55	-69.64	-42.26	-21.57	-7.28

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q